MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

By sjmartinez • November 10, 2023

Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PMID: 37945286.

Tags: Ankylosing, Antirheumatic Agents, Arthritis, Psoriatic, Publications, Rheumatoid, Rheumatology, Spondylitis

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds[...]

Non-Rigid Motion-Compensated MR Multitasking for Free-Breathing Low-Dose Dynamic Contrast-Enhanced MRI in the Abdomen

Ma L, Wu C, Wang L, Lee HL, Chen J, Hu Z, Xie Y, Pandol SJ, Gaddam S, Li D, Christodoulou AG. Non-Rigid Motion-Compensated MR[...]

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]